Risk-benefit assessment of hepatitis B vaccination in France, 2006;Évaluer le rapport bénéfices/risques de la vaccination contre l'hépatite B en France en 2006

Revue de Medecine Interne

Volumn 27, Issue 1, 2006, Pages 40-45

  Hanslik, T ^a,b   Valleron, A J ^a,c   Flahault, A ^a,c  

^a INSERM   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Adverse event; Epidemiology; Hepatitis B; Immunisation; Risk benefit; Vaccine

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

CENTRAL NERVOUS SYSTEM DISEASE; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; EPIDEMIOLOGICAL DATA; FRANCE; HEPATITIS B; HUMAN; IMMUNIZATION; INCIDENCE; REVIEW; RISK BENEFIT ANALYSIS; VACCINATION; VACCINATION REACTION; VIRUS TRANSMISSION; ADULT; HETEROZYGOTE; IMMUNOLOGY; RISK ASSESSMENT; STATISTICS;

ADULT; CARRIER STATE; FRANCE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION; INCIDENCE; RISK ASSESSMENT;

EID: 29944435577     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2005.06.001     Document Type: Short Survey

References (45)

1. o:28-29 2004
2. A.J. Hall Hepatitis B vaccination: protection for how long and against what? BMJ 307 1993 276 277
3. M.H. Chang, C.J. Chen, M.S. Lai, H.M. Hsu, T.C. Wu, and M.S. Kong Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan childhood hepatoma study group N. Engl. J. Med. 336 1997 1855 1859
4. F.J. Mahoney, and M. Kane Hepatitis B vaccine S.O. Plotkin Vaccines 1999 W.B. Saunders compagny Philadelphia 158 182
5. H. Whittle, S. Jaffar, M. Wansbrough, M. Mendy, U. Dumpis, and A. Collinson Observational study of vaccine efficacy 14:years after trial of hepatitis B vaccination in Gambian children BMJ 325 2002 569
6. CDC Protection against viral hepatitis. Recommendations of the Immunization Practices Advisory Committee (ACIP) MMWR Recomm. Rep. 39 RR-2 1990 1 26
7. European consensus group on Hepatitis B immunity Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355 2000 561 565
8. Y.C. Lin, M.H. Chang, Y.H. Ni, H.Y. Hsu, and D.S. Chen Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan J. Infect. Dis. 187 2003 134 138
9. A.J. Roome, S.J. Walsh, M.L. Cartter, and J.L. Hadler Hepatitis B vaccine responsiveness in Connecticut public safety personnel JAMA 270 1993 2931 2934
10. A.S. Rosman, P. Basu, K. Galvin, and C.S. Lieber Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial Am. J. Med. 103 1997 217 222
11. R.C. Wood, K.L. MacDonald, K.E. White, C.W. Hedberg, M. Hanson, and M.T. Osterholm Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers JAMA 270 1993 2935 2939
12. M. Rumi, M. Colombo, R. Romeo, A. Boschini, A. Zanetti, and A. Gringeri Suboptimal response to hepatitis B vaccine in drug users Arch. Intern. Med. 151 1991 574 578
13. U. Laukamm-Josten, G. von Laer, H. Feldmeier, U. Bienzle, A. Uy, and R. Thomssen Active immunization against hepatitis B: immunogenicity of a recombinant DNA vaccine in females, heterosexual and homosexual males Postgrad. Med. J. 63 Suppl 2 1987 143 146
14. V. Massari, P. Maison, J.C. Desenclos, and A. Flahault Six years of sentinel surveillance of hepatitis B in general practice in France Eur. J. Epidemiol. 14 1998 765 767
15. A. Goudeau, and F. Dubois Incidence and prevalence of hepatitis B in France Vaccine 13 Suppl 1 1995 S22 S25
16. A. Meheus Risk of hepatitis B in adolescence and young adulthood Vaccine 13 Suppl 1 1995 S31 S34
17. Réseau Sentinelles. http://rhone.b3e.jussieu.fr/senti/php/doc/ bilans/2002/Bilan_2002_Version2.pdf〉.
18. Réseau Sentinelles. 〈http://rhone.b3e.jussieu.fr/senti/php/ doc/bilans/2001/bilan_final_2001.html〉.
19. S.T. Goldstein, M.J. Alter, I.T. Williams, L.A. Moyer, F.N. Judson, and K. Mottram Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs J. Infect. Dis. 185 2002 713 719
20. Institut veille sanitaire Estimation des taux de pŕvalence des anticorps anti-VHC et des marqueurs du virus de l'h́patite B chez les assuŕs sociaux du ŕgime ǵńral de France ḿtropolitaine, 2003-2004. Analyse descriptive janvier 2005 (14 f́vrier 2005)
21. A. Fhima, R. Henrion, W. Lowenstein, and Y. Charpak Suivi ̀ deux ans d'une cohorte de patients d́pendants aux opiaćs trait́s par bupŕnorphine haut dosage (Subutex®) Ann. Med. Interne (Paris) 152 Suppl 3 2001 IS26 IS36
22. V. Thibault Infections nosocomiales dues au virus de l'h́patite B Ann. Biol. Clin. (Paris) 59 Spec No 2001 12 18
23. GERES. Complément au rapport GERES sur les accidents exposant au sang et le risque de transmission de soignant à patient, 1998. 〈http://www.sante.gouv.fr/htm/pointsur/contamination/compleme.pdf〉.
24. GERES. Rapport GERES sur les accidents exposant au sang et le risque de transmission peropératoire de soignant à patient, 1997. 〈http://www.sante.gouv.fr/htm/pointsur/contamination/rapport.pdf〉.
25. I. Grotto, Y. Mandel, M. Ephros, I. Ashkenazi, and J. Shemer Major adverse reactions to yeast-derived hepatitis B vaccines: a review Vaccine 16 1998 329 334
26. Dartigues JF. Mission d'expertise sur la politique de vaccination contre l'hépatite B en France, 2002. 〈www.sante.gouv.fr/htm/pointsur/ vaccins/dartigues.pdf〉.
27. R.T. Chen, R. Pless, and F. Destefano Epidemiology of autoimmune reactions induced by vaccination J. Autoimmun. 16 2001 309 318
28. AFSSAPS Vaccins contre l'h́patite B:: ŕsuḿ des d́bats de la commission nationale de pharmacovigilance du 21 septembre 2004
29. E. Touze, O. Gout, M.H. Verdier-Taillefer, O. Lyon-Caen, and A. Alperovitch Premier ́pisode de d́mýlinisation du syst̀me nerveux central et vaccination contre l'h́patite B Rev. Neurol. (Paris) 156 2000 242 246
30. E. Touze, A. Fourrier, C. Rue-Fenouche, V. Ronde-Oustau, I. Jeantaud, and B. Begaud Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study Neuroepidemiology 21 2002 180 186
31. M.C. Sturkenboom, L. Abenhaim, C. Wolfson, E. Roullet, O. Heinzlef, and O. Gout Vaccinations, demylenation and multiple sclerosis study (VDAMS). A population-based study in the UK Pharmacoepidemiol. Drug Saf. 8 Suppl 2 1999 S170 S171
32. A. Ascherio, S.M. Zhang, M.A. Hernan, M.J. Olek, P.M. Coplan, and K. Brodovicz Hepatitis B vaccination and the risk of multiple sclerosis N. Engl. J. Med. 344 2001 327 332
33. C. Confavreux, S. Suissa, P. Saddier, V. Bourdes, and S. Vukusic Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group N. Engl. J. Med. 344 2001 319 326
34. F. DeStefano, T. Verstraeten, L.A. Jackson, C.A. Okoro, P. Benson, and S.B. Black Vaccinations and risk of central nervous system demyelinating diseases in adults Arch. Neurol. 60 2003 504 509
35. M.A. Hernan, S.S. Jick, M.J. Olek, and H. Jick Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study Neurology 63 2004 838 842
36. A.D. Sadovnick, and D.W. Scheifele School-based hepatitis B vaccination programme and adolescent multiple sclerosis Lancet 355 2000 549 550
37. F. Zipp, J.G. Weil, and K.M. Einhaupl No increase in demyelinating diseases after hepatitis B vaccination Nat. Med. 5 1999 964 965
38. D. Levy-Bruhl, J.C. Desenclos, I. Rebiere, and J. Drucker Central demyelinating disorders and hepatitis B vaccination: a risk-benefit approach for pre-adolescent vaccination in France Vaccine 20 2002 2065 2071
39. M.E. Tosti, G. Traversa, E. Bianco, and A. Mele Multiple sclerosis and vaccination against hepatitis B: analysis of risk benefit profile Ital. J. Gastroenterol. Hepatol. 31 1999 388 391
40. P. Beutels, W.J. Edmunds, F. Antonanzas, G.A. De Wit, D. Evans, and R. Feilden Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis Pharmacoeconomics 20 2002 1 7
41. M.A. Kane Commentary: public perception and the safety of immunization Vaccine 16 Suppl 1998 S73 S75
42. T. Hanslik, B. Wechsler, J.N. Vaillant, L. Audrain, J. Prinseau, and A. Baglin A survey of physicians' vaccine risk perception and immunization practices for subjects with immunological diseases Vaccine 19 2000 908 915
43. P. Slovic Perception of risk Science 236 1987 280 285
44. AFSSAPS ANAES Inserm Ŕunion de consensus:: vaccination contre le virus de l'h́patite B. Paris septembre 2003 11
45. Afssaps Anaes Inserm Vaccination contre le virus de l'h́patite B et scĺrose en plaques:: ́tat des lieux. Paris novembre 2004 9